SEK 0.01
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - SEK | 0.0% |
2022 | - SEK | -100.0% |
2021 | 38 Thousand SEK | 442.86% |
2020 | 7000.00 SEK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - SEK | 0.0% |
2024 Q2 | - SEK | 0.0% |
2024 Q3 | - SEK | 0.0% |
2023 FY | - SEK | 0.0% |
2023 Q4 | - SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2023 Q3 | - SEK | 0.0% |
2022 Q4 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 Q2 | - SEK | 0.0% |
2022 Q1 | - SEK | 0.0% |
2022 FY | - SEK | -100.0% |
2021 Q1 | 16 Thousand SEK | 0.0% |
2021 Q4 | - SEK | -100.0% |
2021 FY | 38 Thousand SEK | 442.86% |
2021 Q3 | 10 Thousand SEK | -9.09% |
2021 Q2 | 11 Thousand SEK | -31.25% |
2020 Q3 | - SEK | 0.0% |
2020 FY | 7000.00 SEK | 0.0% |
2020 Q2 | - SEK | 0.0% |
2020 Q4 | - SEK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AroCell AB (publ) | 43.03 Million SEK | 100.0% |
Devyser Diagnostics AB (publ) | 169.3 Million SEK | 100.0% |
Immunovia AB (publ) | 1.57 Million SEK | 100.0% |
Prostatype Genomics AB (publ) | 1.35 Million SEK | 100.0% |
SenzaGen AB | 49.87 Million SEK | 100.0% |